Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

Maria Teresa Voso, Luana Fianchi, Giuseppe Leone, Massimo Breccia, Monia Lunghi, Antonella Poloni, Pasquale Niscola, Carlo Finelli, Alessia Bari, Pellegrino Musto, Renato Zambello, Giuliana Alimena

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

32 Citazioni (Scopus)

Abstract

In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important as prognosis post-relapse is poor. There is also the concern that early termination of treatment may result in rapid disease progression. We reviewed outcomes in 13 patients who discontinued azacitidine (decitabine in one patient), while still responding to the treatment. Most patients rapidly relapsed; median time to progression was 5.4 months. Reasons for treatment discontinuation included comorbidities, infections and patient choice. These findings illustrate the risk of prematurely terminating azacitidine therapy in MDS. © 2013 John Wiley & Sons A/S.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaEuropean Journal of Haematology
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • AZACITIDINE

Fingerprint

Entra nei temi di ricerca di 'Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia'. Insieme formano una fingerprint unica.

Cita questo